All News

FDA.approved.jpg

FDA Approves Anifrolumab in SLE

d Jack Cush, MD

AstraZeneca announced today that anifrolumab (Saphnelo or anifrolumab-fnia) was approved by the the Food and Drug Administration (FDA) for that treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.  

Read Article
Fatigue, FM, fibromyalgia

Fibromyalgianess Influences Steroid Persistence

d Jack Cush, MD

"Fibromyalgianess" is highlighted as a risk factor for undue, extended glucocorticoid use in rheumatoid arthritis (RA) patients, according to Wallace and colleagues in Rheumatology.

Read Article
RheumNow Podcast square

RheumNow Podcast – Psoriatic Arthritis Without Psoriasis (7.30.2021)

d Jack Cush, MD

How much psoriasis do you need to have in order to have psoriatic arthritis? This plus a review of rheumatology and COVID news from the past week on RheumNow.com.

Read Article
FDA Approves Anifrolumab in active, moderate-severe SLE on background standard of care therapies. https://t.co/22HVA32IAh https://t.co/NxJ4sWTWfE

Links:

Dr. John Cush RheumNow ( View Tweet)

Registry data suggests an increased risk of herpes zoster (HZ, shingles) in rheumatoid arthritis (RA) patients taking JAK inhibitors (JAKi) but also with other biologic DMARDs, compared to csDMARDs. https://t.co/Uu1VjAbKMi https://t.co/uGvTyLExjf

Links:

Dr. John Cush RheumNow ( View Tweet)
The ARTIS Study Group has published their analysis of (non-skin) cancer risk in rheumatoid arthritis, claiming the overall safety of biologic DMARDs and targeted synthetic DMARDs (tsDMARDs). https://t.co/RNWrLR53Wx https://t.co/mMmKKrX9vx

Links:

Dr. John Cush RheumNow ( View Tweet)
Health personnel (HCP) @ long-term care facilities (LTCFs) are at high risk for COVID-19. March 2021, 57% of LTCF HCPs were vaccinated. COVID-19 vax was highest in MDs (75.1%); lowest nurses (56.7%) & aides (45.6%). https://t.co/VjHutcrh26 https://t.co/8aO1mFgC8f

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: The FDA has authorized baricitinib ALONE as treatment for COVID-19 hospitalized adults and pediatric patients requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) https://t.co/WMc78GmOLU https://t.co/Bp5tL4pRk5

Links:

Dr. John Cush RheumNow ( View Tweet)
Worth another share-- Turning the Corner on CV Risk in Rheumatoid Arthritis by Richard Conway ( @RichardPAConway) #EULAR2021 https://t.co/S0ownscRKv https://t.co/7QtynRKAd6

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: One of our top June videos WATCH: Is blindness with Tocilizumab in GCA a worry? Dr. David Liew ( @drdavidliew ) weighs in. #EULAR2021 https://t.co/eFrmbkW9Gy https://t.co/4tY3hEDj2j

Links:

Dr. John Cush RheumNow ( View Tweet)
Pain Persists in RA, Even Without Inflammation One-third of patients with rheumatoid arthritis had unacceptably high levels of pain 5 years after diagnosis, often despite low levels of inflammation, Swedish researchers found. https://t.co/K8zf1pE9jM https://t.co/aEBu7jVHft

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Podcast – Psoriatic Arthritis Without Psoriasis Download wherever you get your podcasts! https://t.co/Ra5f7507XT https://t.co/5WqPCgGVpr

Links:

Dr. John Cush RheumNow ( View Tweet)
Did you see this tweet from May? Worth re-sharing. Rituximab Tops Mycophenolate Mofetil for Pemphigus Vulgaris. One year study of 135 moderate-to-severe pemphigus patients saw complete remission in 40% of RTX vs 10% of MMF patients. https://t.co/yAauFRjHCe https://t.co/bibHXaHtWf

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Belimumab now approved in the EU for lupus nephritis. The EMA has approved intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for adults with active lupus nephritis https://t.co/Twbe1ClT5w

Links:

Dr. John Cush RheumNow ( View Tweet)

New podcast available for download! We focus on the articles shared this week on https://t.co/V10S4oVFsv . https://t.co/Ra5f7507XT https://t.co/Pz0RFxLIOx

Links:

Dr. John Cush RheumNow ( View Tweet)
Swiss SCQM registry compared 3217 RA & 819 PsA pts; PsA had more obese (36.5% overweight, 23.8% obese) than RA (4.4% underweight, 31.8% overweight, 17.0% obese). Obese PsA had higher CRP, Dz activity, worse QOL, pain & skin https://t.co/UzbKlT3tSz

Links:

Dr. John Cush RheumNow ( View Tweet)

Literature review examined safety of IL-17 inhibitors in 106 controlled RCTs, 40,053 pts. Inflammatory bowel disease was reported in 0.4% of IL-17i Rx patients. (same in 61 uncontrolled RCTs -0.36%). Other AE: diarrhea (2.5%), N/V(0.7%) https://t.co/2wSZQqB1Zs

Links:

Dr. John Cush RheumNow ( View Tweet)

JAMA article on using new features in Updated PubMed: 1) Focus the Clinical Question 2) Use PubMed Clinical Query Filters 3) Refine the Search Terms https://t.co/ExK8p2hVnX

Links:

Dr. John Cush RheumNow ( View Tweet)

Comparison of 1040 elderly-onset RA (EORA) and 710 non-EORA patients showed similar disease activity, DMARD choices, drug response rates and reasons for Rx discontinuation - There's no reason EORA shouldn't be treated as aggressive as all RA! https://t.co/P2gpPlJVZE

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Drugs capable of inducing drug-associated ANCA vasculitis - mirabegron (Myrbetriq), sofosbuvir (Sovaldi, antiviral), nintedanib (Ofev), hydralazine, propylthiouracil, thiamazole, minocycline, carbimazole, allopurinol, influenza vax.... https://t.co/KhK2w0IGAx

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×